Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics (RLFTY) has released its 2024 Annual Report, highlighting operational achievements and pipeline progress. The company's chairman, Dr. Raghuram Selvaraju, emphasized their strengthened financial position and commitment to treating rare diseases.
Key developments include advancement of two core pipeline products:
- RLF-OD032: A next-generation liquid sapropterin formulation for phenylketonuria
- RLF-TD011: A proprietary hypochlorous acid solution for epidermolysis bullosa
The company anticipates significant clinical and regulatory milestones in 2025 as they continue to focus on delivering treatments for unmet medical needs.
Relief Therapeutics (RLFTY) ha pubblicato il suo Rapporto Annuale 2024, evidenziando i successi operativi e i progressi nel proprio pipeline. Il presidente dell'azienda, Dr. Raghuram Selvaraju, ha sottolineato la loro posizione finanziaria rafforzata e l'impegno nel trattamento delle malattie rare.
I principali sviluppi includono l'avanzamento di due prodotti chiave nel pipeline:
- RLF-OD032: Una formulazione liquida di sapropterina di nuova generazione per la fenilchetonuria
- RLF-TD011: Una soluzione proprietaria di acido ipocloroso per l'epidermolisi bollosa
L'azienda prevede significativi traguardi clinici e regolatori nel 2025 mentre continua a concentrarsi sulla fornitura di trattamenti per bisogni medici insoddisfatti.
Relief Therapeutics (RLFTY) ha publicado su Informe Anual 2024, destacando los logros operativos y los avances en su pipeline. El presidente de la empresa, Dr. Raghuram Selvaraju, enfatizó su posición financiera fortalecida y el compromiso con el tratamiento de enfermedades raras.
Los desarrollos clave incluyen el avance de dos productos principales en el pipeline:
- RLF-OD032: Una formulación líquida de sapropterina de nueva generación para la fenilcetonuria
- RLF-TD011: Una solución propietaria de ácido hipocloroso para la epidermólisis bullosa
La empresa anticipa hitos clínicos y regulatorios significativos en 2025 mientras continúa enfocándose en ofrecer tratamientos para necesidades médicas no satisfechas.
Relief Therapeutics (RLFTY)는 2024년 연례 보고서를 발표하며 운영 성과와 파이프라인 진행 상황을 강조했습니다. 회사의 회장인 Dr. Raghuram Selvaraju는 강화된 재무 상태와 희귀 질환 치료에 대한 의지를 강조했습니다.
주요 개발 사항으로는 두 가지 핵심 파이프라인 제품의 발전이 포함됩니다:
- RLF-OD032: 페닐케톤뇨를 위한 차세대 액상 사프로테린 제형
- RLF-TD011: 표피박리증을 위한 독점적인 차아염소산 용액
회사는 2025년에 중요한 임상 및 규제 이정표를 예상하며, 충족되지 않은 의료 필요에 대한 치료 제공에 계속 집중할 것입니다.
Relief Therapeutics (RLFTY) a publié son Rapport Annuel 2024, mettant en avant les réalisations opérationnelles et les progrès de son pipeline. Le président de la société, Dr. Raghuram Selvaraju, a souligné leur position financière renforcée et leur engagement à traiter les maladies rares.
Les développements clés incluent l'avancement de deux produits principaux dans le pipeline :
- RLF-OD032: Une formulation liquide de sapropterine de nouvelle génération pour la phénylcétonurie
- RLF-TD011: Une solution propriétaire d'acide hypochloreux pour l'épidermolyse bulleuse
La société anticipe des jalons cliniques et réglementaires significatifs en 2025 alors qu'elle continue de se concentrer sur la fourniture de traitements pour des besoins médicaux non satisfaits.
Relief Therapeutics (RLFTY) hat seinen Jahresbericht 2024 veröffentlicht und dabei betriebliche Erfolge sowie Fortschritte in der Pipeline hervorgehoben. Der Vorsitzende des Unternehmens, Dr. Raghuram Selvaraju, betonte die gestärkte finanzielle Lage und das Engagement zur Behandlung seltener Krankheiten.
Wichtige Entwicklungen umfassen den Fortschritt von zwei Kernprodukten in der Pipeline:
- RLF-OD032: Eine neuartige flüssige Sapropterin-Formulierung für Phenylketonurie
- RLF-TD011: Eine proprietäre Lösung aus hypochloriger Säure für die Epidermolysis bullosa
Das Unternehmen erwartet im Jahr 2025 bedeutende klinische und regulatorische Meilensteine, während es weiterhin darauf abzielt, Behandlungen für unerfüllte medizinische Bedürfnisse bereitzustellen.
- Pipeline advancement of two key drug candidates
- Strengthened financial position reported
- Multiple clinical and regulatory milestones expected in 2025
- None.
GENEVA, SWITZERLAND / ACCESS Newswire / April 10, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its 2024 Annual Report and provided a corporate update.
In his annual letter to shareholders, Dr. Raghuram Selvaraju, chairman of the board of directors, emphasized the Company's operational achievements, pipeline momentum, and strengthened financial position. "This past year, we built a stronger foundation and made measurable progress in executing our plans as we advanced our core pipeline and optimized our commercial strategy, always guided by our commitment to delivering meaningful solutions for patients with unmet medical needs," said Dr. Selvaraju. "We are particularly excited by the continued progress of RLF-OD032, our next-generation liquid sapropterin formulation for phenylketonuria, and RLF-TD011, our proprietary hypochlorous acid solution for epidermolysis bullosa. We look forward to important clinical and regulatory milestones in 2025."
Relief's 2024 Annual Report, which includes pipeline and portfolio updates, corporate governance and compensation disclosures, and financial statements, is available on the Company's website .
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company dedicated to advancing treatment paradigms and improving the lives of patients with rare and debilitating diseases. With core expertise in drug delivery systems and drug repurposing, Relief's clinical pipeline includes innovative treatments designed to address critical unmet medical needs in rare dermatological, metabolic and respiratory conditions. The Company has also successfully brought several approved products to market through licensing and distribution partnerships. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com
CONTACT
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as "believe," "assume," "expect," "intend," "may," "could," "will," or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, but are not limited to, changes in economic conditions, market developments, regulatory changes, competitive dynamics, and other risks or changes in circumstances. This communication is provided as of the date hereof, and Relief undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
SOURCE: Relief Therapeutics Holding SA
View the original press release on ACCESS Newswire
FAQ
What are the key pipeline products highlighted in Relief Therapeutics (RLFTY) 2024 annual report?
What major milestones does RLFTY expect in 2025?
What is the purpose of Relief Therapeutics' RLF-OD032 drug candidate?
What therapeutic area is Relief Therapeutics' RLF-TD011 targeting?
